vosaroxin: Clinical Trials

7 trials of vosaroxin, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed. 7 Phase 1, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 17Completed 7
Phase 23Completed 3

Follow vosaroxin: new trials by email Literature Review of vosaroxin trials Research Report on vosaroxin

Trials (filtered) newest first · largest first

All 7 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes
vosaroxin, Azacitidine - Myelodysplastic Syndromes
Phase 1CompletedWashington University School of Medicine352013-11-222024-05-02
Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy
Vosaroxin - Myelodysplastic Syndrome
Phase 1 / Phase 2CompletedWeill Medical College of Cornell University102013-10-252019-02-19
Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
Vosaroxin, Decitabine - Leukemia
Phase 1 / Phase 2CompletedM.D. Anderson Cancer Center662013-07-182022-02-09
Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans
Voreloxin injection and cytarabine - Acute Myeloid Leukemia
Phase 1 / Phase 2CompletedSunesis Pharmaceuticals1102007-10-062018-01-09
Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
Vosaroxin - Leukemia, Lymphocytic, Acute, Leukemia, Nonlymphocytic, Acute
Phase 1CompletedSunesis Pharmaceuticals752005-11-142017-03-30
Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors
SNS-595 - Neoplasms
Phase 1CompletedSunesis Pharmaceuticals2004-10-012007-05-10
Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors.
SNS-595 - Neoplasms
Phase 1CompletedSunesis Pharmaceuticals2004-06-012007-05-10

Conditions studied

Neoplasms (4)  ·  Leukemia (3)  ·  Leukemia, Myeloid, Acute (3)  ·  Myelodysplastic Syndromes (3)  ·  Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1)  ·  Leukemia, Myelomonocytic, Chronic (1)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (1)  ·  Recurrence (1)

Sponsors

Sunesis Pharmaceuticals (4)  ·  M.D. Anderson Cancer Center (1)  ·  Washington University School of Medicine (1)  ·  Weill Medical College of Cornell University (1)

Countries

United States (7)

Top investigators

Daniel C. Adelman, MD (2)  ·  Gail Roboz, MD (1)  ·  Glenn Michelson, MD (1)  ·  Meagan Jacoby, M.D., Ph.D. (1)  ·  Naval Daver, MD (1)

Results publications

PMID 25381131, PMID 28729302